Family History
411 articles
Listen to Your Body
When Roxanne Waling discovered she had pancreatic cancer she underwent genetic testing. She found she was a BRCA2 carrier, which influenced her post-treatment decisions about her health.
Focusing on a Drug that Treats Specific Tumor Mutations
A clinical trial tests a signal-inhibiting drug for lung cancers with specific genetic mutations on gastrointestinal cancers with the same tumor mutations.
New Drug for BRCA Carriers with Advanced Cancer
A phase I clinical trial is testing the effectiveness of a platinum-based drug for BRCA carriers with pancreatic, breast, and other cancers.
Chemotherapy Plus Stem Cell Infusion and Vitamins for BRCA Mutated Pancreatic Cancer
A clinical trial for pancreatic cancer patients with a BRCA mutation uses a combination of chemotherapy, vitamins, and stem cells.
Testing a PARP Inhibitor for Metastatic Pancreatic Cancer Patients with DNA Repair Mutations
Researchers are testing a PARP inhibitor that is effective for cancers in pancreatic cancer patients with DNA repair mutations.
Using Molecular Tumor Profiling to Determine the Best Pancreatic Cancer Treatment
A clinical trial looks at whether molecular subtyping of tumors is effective in determining the best pancreatic cancer treatment.
Testing an Approved Drug for a Specific Mutation
Researchers are testing a drug combination for melanoma in pancreatic cancer patients with a BRAF genetic mutation.
New Gene Inhibitor Drug for Patients with MTAP-Deleted Tumors
A new trial targets patients with advanced solid tumors, including pancreatic cancer, with an MTAP-deletion genetic mutation.
A Potential Role for PARP Inhibitors in Pancreatic Cancer
Dr. Michael Pishvaian leads research into the possible role of PARP inhibitors in treating pancreatic cancer patients with certain genetic mutations.
PARP Inhibitors for Pancreatic Cancer Maintenance Treatment
Dr. Kim Reiss Binder is leading a clinical trial of maintenance treatment with the PARP inhibitor rucaparib, for patients who carry the BRCA mutation.
A PARP Inhibitor Approval for Pancreatic Cancer
PARP inhibitors, a type of targeted therapy, are being studied as treatment for pancreatic cancer in a number of clinical trials.
Dousing Out-of-Control KRAS Signaling in Pancreatic Cancer
Rene Bernards and his team are targeting the signaling pathway of the KRAS mutation, which occurs in almost all pancreatic cancers.
Exploiting DNA Mutations For Pancreatic Cancer Treatment
Dr. James Cleary explains how the researchers at Dana-Farber are looking to make PARP inhibitors even more effective for pancreatic cancer patients.
Targeting Mutant KRAS with Immunotherapy
Dr. Beatriz Carreno explains how her team is targeting the KRAS mutation with a pancreatic cancer vaccine to make the immune system work against cancer.
Targeting the Undruggable KRAS Protein
Dr. Shubham Pant is focusing his research on effective treatments for the KRAS mutation, found in 90% of pancreatic cancers.